AIM
VRTX icon

ARK Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

ARK Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,100
Closed -$11.8M – 207
2025
Q4 		$11.8M Buy
26,100
+435
+2% +$187K 0.08% 106
2025
Q3 		$10.1M Buy
25,665
+1,602
+7% +$670K 0.06% 114
2025
Q2 		$10.7M Sell
24,063
-2,281
-9% -$1.05M 0.08% 96
2025
Q1 		$12.8M Buy
26,344
+994
+4% +$463K 0.13% 80
2024
Q4 		$10.2M Sell
25,350
-25,749
-50% -$11.9M 0.09% 93
2024
Q3 		$23.8M Sell
51,099
-24,365
-32% -$11.7M 0.22% 60
2024
Q2 		$35.4M Sell
75,464
-14,640
-16% -$6.35M 0.31% 49
2024
Q1 		$37.7M Sell
90,104
-34,093
-27% -$14.4M 0.26% 58
2023
Q4 		$50.5M Buy
124,197
+8,866
+8% +$3.28M 0.3% 46
2023
Q3 		$40.1M Sell
115,331
-340
-0.3% -$119K 0.31% 46
2023
Q2 		$40.7M Sell
115,671
-4,838
-4% -$1.63M 0.27% 45
2023
Q1 		$38M Sell
120,509
-1,688
-1% -$506K 0.26% 47
2022
Q4 		$35.3M Sell
122,197
-35,248
-22% -$10.7M 0.31% 47
2022
Q3 		$45.6M Sell
157,445
-208,077
-57% -$59.9M 0.32% 49
2022
Q2 		$98.2M Sell
365,522
-56,253
-13% -$15.1M 0.58% 36
2022
Q1 		$110M Sell
421,775
-507,016
-55% -$120M 0.46% 39
2021
Q4 		$204M Sell
928,791
-780,960
-46% -$152M 0.62% 36
2021
Q3 		$310M Sell
1,709,751
-64,315
-4% -$12.6M 0.74% 33
2021
Q2 		$358M Buy
1,774,066
+55,020
+3% +$11.5M 0.67% 42
2021
Q1 		$369M Buy
1,719,046
+902,852
+111% +$198M 0.73% 42
2020
Q4 		$193M Buy
816,194
+718,842
+738% +$165M 0.51% 52
2020
Q3 		$26.5M Buy
+97,352
New +$26.9M 0.16% 71

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ARK Investment Management's VRTX Position: Q1 2026 in Review

ARK Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 26,100 shares — an estimated $11.8M sold.

ARK Investment Management first reported a position in VRTX in Q3 2020 and held it in 22 quarters. The position peaked at $369M in Q1 2021. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • ARK Investment Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • ARK Investment Management sold 26,100 Vertex Pharmaceuticals shares in Q1 2026, an estimated $11.8M.
  • ARK Investment Management first reported a position in Vertex Pharmaceuticals in Q3 2020 and held it in 22 quarters.
  • ARK Investment Management's Vertex Pharmaceuticals position peaked at $369M in Q1 2021.
  • 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on ARK Investment Management's 13F filing for Q1 2026, filed 12 May 2026.